



Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Body weight changes in SNU-1066 xenograft model administered saline or cetuximab. Body weight was monitored three times a week during therapy. No significant weight loss was observed in saline (control) and cetuximab treatment groups.



Supplementary Figure 2: Body weight changes in SNU-1066 xenograft model administered saline, cetuximab or ¹⁷⁷Lu-PCTA-cetuximab. Body weight was monitored three times a week during therapy. No significant weight loss was observed in saline (control), cetuximab and ¹⁷⁷Lu-PCTA-cetuximab treatment groups.